JP2005520795A5 - - Google Patents

Download PDF

Info

Publication number
JP2005520795A5
JP2005520795A5 JP2003551316A JP2003551316A JP2005520795A5 JP 2005520795 A5 JP2005520795 A5 JP 2005520795A5 JP 2003551316 A JP2003551316 A JP 2003551316A JP 2003551316 A JP2003551316 A JP 2003551316A JP 2005520795 A5 JP2005520795 A5 JP 2005520795A5
Authority
JP
Japan
Prior art keywords
hsp90
high affinity
assay
compound
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003551316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005520795A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/039993 external-priority patent/WO2003050295A2/en
Publication of JP2005520795A publication Critical patent/JP2005520795A/ja
Publication of JP2005520795A5 publication Critical patent/JP2005520795A5/ja
Pending legal-status Critical Current

Links

JP2003551316A 2001-12-12 2002-12-12 Ｈｓｐ９０阻害活性を有するプリン類似体 Pending JP2005520795A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34076201P 2001-12-12 2001-12-12
PCT/US2002/039993 WO2003050295A2 (en) 2001-12-12 2002-12-12 Assays and implements for determining and modulating hsp90 binding activity

Publications (2)

Publication Number Publication Date
JP2005520795A JP2005520795A (ja) 2005-07-14
JP2005520795A5 true JP2005520795A5 (enExample) 2006-02-02

Family

ID=23334832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003551316A Pending JP2005520795A (ja) 2001-12-12 2002-12-12 Ｈｓｐ９０阻害活性を有するプリン類似体

Country Status (6)

Country Link
US (2) US20050074457A1 (enExample)
EP (1) EP1519735A4 (enExample)
JP (1) JP2005520795A (enExample)
AU (1) AU2002364566B2 (enExample)
CA (1) CA2468202A1 (enExample)
WO (1) WO2003050295A2 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670113B2 (en) * 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
US7892781B2 (en) * 2001-03-30 2011-02-22 Nanoprobes, Inc. Detecting a target using a composite probe comprising a directing agent, a metal nanoparticle and an enzyme
US7888060B2 (en) * 2001-03-30 2011-02-15 Nanoprobes, Inc. Method for detecting a target using enzyme directed deposition of elemental metal
US7691598B2 (en) * 2001-03-30 2010-04-06 Nanoprobes, Inc. Method for detecting a target molecule by metal deposition
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US7465718B2 (en) 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
JPWO2004024141A1 (ja) * 2002-08-29 2006-01-05 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
EP1583961B1 (en) * 2002-12-20 2007-03-21 The Registrar, Indian Institute of Science A novel assay to screen for anti-malarials
WO2004069999A2 (ja) * 2003-02-04 2004-08-19 Takeda Pharmaceutical Company Limited スクリーニング方法
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
US7282493B2 (en) * 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US20050267087A1 (en) * 2004-04-28 2005-12-01 Vassiliki Poulaki Inflammatory eye disease
US7259156B2 (en) * 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
BRPI0517268A (pt) * 2004-11-02 2008-10-07 Conforma Therapeutics Corp método para tratar uma forma de leucemia linfocìtica crÈnica
US20080193932A1 (en) * 2004-11-05 2008-08-14 University Of Rochester Methods Of Inhibiting the Activity of Hsp90 and/or Aryl Hydrocarbon Receptor
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
JP5465006B2 (ja) 2006-08-11 2014-04-09 ユニベルシテ・ドウ・ストラスブール キナーゼおよびｈｓｐ９０の阻害剤として有用な大環状化合物
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
BRPI0812970A2 (pt) * 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
DE102011106984B3 (de) * 2011-07-08 2012-10-11 Sartorius Stedim Biotech Gmbh Microarray-Vorrichtung für das Screenen oder Auffinden von HSP90 Inhibitoren und von Inhibitoren weiterer krankheitsrelevanter Zielstrukturen
ES2624982T3 (es) * 2011-07-08 2017-07-18 Sloan-Kettering Institute For Cancer Research Usos de inhibidores etiquetados HSP90
US9575056B2 (en) * 2011-07-22 2017-02-21 Access Bio, Inc. Single-pad strip for an improved lateral flow assay and a test device using the same
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN116425875A (zh) 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3529276A4 (en) * 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
US11377447B2 (en) 2017-06-20 2022-07-05 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
PH12022551160A1 (en) 2019-11-15 2023-09-25 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL334257A1 (en) * 1999-07-06 2001-01-15 Cierpiak Andrzej Central heating water boiler
WO2001072779A1 (en) * 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto

Similar Documents

Publication Publication Date Title
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
EP1864998A3 (en) Binding molecules
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2007002223A3 (en) Cd19 antibodies and their uses
WO2007000342A3 (en) Immunogenic composition
EP1581656A4 (en) MODULATION OF THE EXPRESSION OF HIF1a AND HIF2a
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
UA97473C2 (ru) Выделенное антитело, которое связывается с her-3, и его применение
WO2002042775A3 (en) Clinically intelligent diagnostic devices and methods
WO2006076691A8 (en) Irta-2 antibodies and their uses
JP2006507484A5 (enExample)
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
WO2005014795A3 (en) Osteoarthritis biomarkers and uses thereof
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
WO2004094610A3 (en) Wnt as a factor for cardiac myogenesis
WO2006078853A3 (en) Thioredoxin interacting protein (txnip) as regulator of vascular function
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
EP2116616A3 (en) Genes differentially expressed in activated T cells and uses thereof
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
JP2005513506A5 (enExample)
CA2428319A1 (en) Compositions and methods for diagnosing or treating psoriasis
WO2005054509A3 (en) Assay and treatment
WO2004038407A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)